Non-alcoholic Fatty Liver Disease

A Big, Fatty Opportunity for Big Pharma The next multibillion-dollar therapeutic area for drug companies may be fatty liver disease, but there are a few practical hurdles to overcome first.  The next big opportunity for pharmaceutical companies is in a disease many people don’t know about. Investors and industry observers should expect to hear…